ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically s